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The United Kingdom is in the fourth season of intro-
ducing a universal childhood influenza vaccine pro-
gramme. The 2016/17 season saw early influenza 
A(H3N2) virus circulation with care home outbreaks 
and increased excess mortality particularly in those 
65 years or older. Virus characterisation data indi-
cated emergence of genetic clusters within the 
A(H3N2) 3C.2a group which the 2016/17 vaccine strain 
belonged to. Methods: The test-negative case–control 
(TNCC) design was used to estimate vaccine effective-
ness (VE) against laboratory confirmed influenza in 
primary care.  Results:  Adjusted end-of-season vac-
cine effectiveness (aVE) estimates were 39.8% (95% 
confidence interval (CI): 23.1 to 52.8) against all influ-
enza and 40.6% (95% CI: 19.0 to 56.3) in 18–64-year-
olds, but no significant aVE in ≥ 65-year-olds. aVE 
was 65.8% (95% CI: 30.3 to 83.2) for 2–17-year-olds 
receiving quadrivalent live attenuated influenza vac-
cine. Discussion: The findings continue to provide sup-
port for the ongoing roll-out of the paediatric vaccine 
programme, with a need for ongoing evaluation. The 
importance of effective interventions to protect the 
≥ 65-year-olds remains.
Introduction
The United Kingdom (UK) has a long-standing influ-
enza selective immunisation programme offering inac-
tivated vaccine to people 65 years of age and older and 
those 6 months to less than 65 years of age with an 
underlying clinical risk factor [1]. Following advice from 
the Joint Committee on Vaccination and Immunisation 
(JCVI), the UK started the incremental introduction of 
a universal childhood influenza vaccine programme in 
the 2013/14 influenza season [2] with a newly licensed 
intra-nasally administered live attenuated influenza 
vaccine (LAIV). Eligible healthy children were offered 
a single dose of LAIV, whereas children in a clinical 
risk group up to 9 years of age, with no contraindica-
tions for LAIV and not previously vaccinated, were 
offered two doses of vaccine. By the 2016/17 season, 
all children aged 2–8 years across the UK were being 
offered quadrivalent LAIV (LAIV4), or else quadrivalent 
inactivated vaccine (QIV) if LAIV4 was contraindicated 
[1]. In addition, Scotland and Northern Ireland offered 
LAIV4 also to all remaining children of primary school 
age up to 11 years of age. The UK has found evidence 
of LAIV4 effectiveness in 2015/16 of 58% and contin-
ues to recommend its use [3]. This is in contrast to the 
United States (US) where there has been a longstand-
ing paediatric influenza vaccination programme, and 
where reduced LAIV vaccine effectiveness (VE) has 
been described by the US Centres for Disease Control 
(CDC). This led to a recommendation to suspend use 
of LAIV in children in 2016/17 [4] and important ques-
tions about what might explain these observations of 
apparent reduced LAIV effectiveness, including what 
role prior vaccination may play [5].
The 2016/17 influenza season in the UK, as with many 
other northern hemisphere countries, was charac-
terised by the early circulation of influenza A(H3N2) 
viruses. The season started in December 2016 and 
peaked over the Christmas/New Year period. It was 
characterised by large numbers of care home out-
breaks, many of which included highly vaccinated 
populations, increased admissions to hospital com-
pared with the previous season and significant excess 
mortality particularly among those 65-year-old or 
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older, despite vaccine uptake levels of over 70% in this 
age group [6]. Questions have been previously raised 
about the effectiveness of inactivated influenza vac-
cine in older persons and a range of potential explana-
tory factors have been postulated including what role 
prior vaccine exposure may play in reducing VE in this 
age group [7].
The UK has a well-established system to monitor influ-
enza VE each season, including mid-season estimates 
based upon sentinel swabbing in primary care [3,8]. 
Here we present the 2016/17 end-of-season VE find-
ings for laboratory-confirmed infection in primary care 
across all age groups, with a particular focus on LAIV4 
in children and inactivated influenza vaccine (IIV) in 
adult age groups and we explore the possible effect of 
prior season vaccination on VE in the current season. 
A comparison with the mid-season estimate is also 
undertaken.
Methods 
The test-negative case–control (TNCC) design was 
used to estimate VE, with the study undertaken in the 
registered population of five sentinel general practice 
(GP) surveillance networks across the UK. All undertake 
respiratory swabbing, with details of these schemes 
outlined previously [3]. The schemes are: the Royal 
College of General Practitioners (RCGP) Research and 
Surveillance Centre (RSC) network, the Public Health 
England (PHE) Specialist Microbiology Network (SMN) 
and the national sentinel schemes of Wales, Scotland 
and Northern Ireland.
The study took place in the period from 1 October 2016, 
the time when influenza surveillance in primary care 
with respiratory swabbing was started, until 19 March 
2017. A mid-season analysis was undertaken for sam-
ples taken up to 15 January 2017, in order to provide 
results to the annual World Health Organization (WHO) 
meeting on the composition of influenza virus vaccines 
for the next influenza season [9]. The study population 
comprised patients presenting to their GP during the 
study period with an acute influenza-like illness (ILI), 
who the physician consented verbally and swabbed 
during the consultation. The majority of the UK influ-
enza vaccine programme is delivered in the period late 
September through to the end November [6].
Definition of cases and controls
A case of ILI was defined as an individual who pre-
sented with an acute respiratory illness with physician-
diagnosed fever or complaint of feverishness in the 
previous 7 days. Participating GPs were asked to invite 
persons presenting with ILI to provide a swab for diag-
nosis. Swabbing was undertaken regardless of vacci-
nation status. Cases were patients who tested positive 
for seasonal influenza A or B virus by real-time PCR 
testing. Controls were patients with the same symp-
toms who tested negative for influenza A or B virus.
Data collection
During the consultation, the GP completed a stand-
ard questionnaire. This collected demographic (age 
and sex), clinical (date of onset and history of fever) 
and epidemiological information from patients includ-
ing vaccination status and potential confounders such 
as underlying clinical risk factors. Vaccination status 
including date of vaccination was obtained mainly from 
patient records. Vaccine type (LAIV4 intranasal; QIV 
injectable) was specified on the form. Time since vac-
cination was stratified into <3 months and  >3 months 
until onset of illness. Study subjects were catego-
rised according to Department of Health defined risk 
categories for influenza vaccination [1]. High risk was 
determined by the presence of well recognised risk mor-
bidities recorded in the electronic health record for the 
patient concerned. In addition, it was noted whether 
the general practice was in a pilot area for England-
based paediatric immunisation schemes, where all pri-
mary school age children were offered LAIV4.
Patients were defined as vaccinated if they were 
reported to have received the 2016/17 seasonal vac-
cine at least 14 days before first onset of symptoms. 
Patients were excluded if they were vaccinated less 
than 14 days before symptom onset. If date of vaccina-
tion was unknown, it was assumed to be 15 October 
2016, which was the median of all known vaccination 
dates this season (data not shown).
Figure 1
Swabbing results of patients with influenza-like illness 
in primary care during the influenza season, United 
Kingdom, October 2016–March 2017
Samples in original dataset
(n=4,251)
Samples included in the analysis
(n=2,881)
Cases (n=659) 
Inﬂuenza A (n=589) 
Inﬂuenza B (n=70)
Controls (n=2,222)
Sequentially excluded samples:
Date of sample prior to 1 Oct 2016 (n=95)
LAIV strain (n=4)
Vaccination status unknown  (n=163)
Vaccination <14 days from onset (n=90)
Date of onset unknown (n=227)
Swab more than 7 days after onset (n=747)
Inﬂuenza status unknown (n=44)
LAIV: live attenuated influenza vaccine.
3www.eurosurveillance.org
Figure 2
Phylogenetic analysis of full length haemagglutinin gene comparing reference sequences from the GISAID EpiFlu database 
and influenza A(H3N2) sequences from patients, United Kingdom, influenza season 2016/17
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GISAID: Global Initiative on Sharing Avian Influenza Data; UK: United Kingdom.
The tree was built using a neighbour-joining algorithm, with vaccine strain A/Texas/50/2012 selected as the root. Signature amino acid 
substitutions characterising genetic groups are annotated at the root of each cluster. UK 2016/17 samples are highlighted in bold. Sentinel 
samples are highlighted in red.
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Registered patients were excluded if they had 
expressed a wish to be, or the practice used one of 
the codes that they may not want to share data (e.g. 
Summary Care Record or Care.data opt-out codes).
Laboratory methods
GPs took combined throat and nose swabs which were 
then sent from the practice to the usual laboratory. 
Samples in England were sent to the PHE Reference Virus 
Unit, Colindale (RCGP scheme) or one of the special-
ist regional microbiology laboratories (SMN scheme). 
Samples in Wales were sent to the Public Health Wales 
Specialist Virology Centre and in Scotland to the West 
of Scotland Specialist Virology Centre (HPS scheme) 
(WoSPV). In Northern Ireland samples were sent to the 
Regional Virus Laboratory, Belfast. Influenza labora-
tory confirmation was made using comparable real-
time PCR methods able to detect circulating influenza 
A and influenza B viruses [10]. All laboratories then 
sent influenza virus-positive detections to the refer-
ence laboratories for further characterisation (RVU in 
London for all schemes except in Scotland where they 
were sent to WoSPV in Glasgow). Isolation of influenza 
viruses was attempted from all suitable PCR positive 
samples using Madin-Darby canine kidney epithelial 
(MDCK) cells or MDCK cells containing the cDNA of 
human 2,6-sialtransferase (SIAT1) cells [11,12].
Virus isolates with a haemagglutination titre ≥ 40 were 
characterised antigenically using post-infection ferret 
antisera in haemagglutination inhibition (HI) assays, 
with guinea pig (A(H3N2) viruses) or turkey (influenza 
B viruses) red blood cells [12]. Reference virus strains 
used for HI assays included A/HongKong/4801/2014, 
B/Brisbane/60/2008, B/Phuket/3073/2013 (vaccine 
strains) and other A(H3N2) and influenza B reference 
strains grown in embryonated chicken eggs and tissue 
culture cells.
Nucleotide sequencing of the haemagglutinin (HA) 
gene of a subset of influenza A(H3N2) and influenza B 
viruses selected to be representative of the range of 
the patients’ age, date of sample collection, geographi-
cal location and antigenic characterisation of the virus 
isolate, if performed, was undertaken. Phylogenetic 
trees of the HA gene of A(H3N2) viruses were con-
structed with a neighbour-joining algorithm available 
in the Mega 6 software (http://www.megasoftware.
net) [13].
HA sequences from reference strains used in the phy-
logenetic analysis were obtained from the EpiFlu data-
base of the Global Initiative on Sharing Avian Influenza 
Data (GISAID) (Table 1). The HA sequences generated 
for this study and used in the phylogenetic analysis, 
Figure 3
Adjustedª vaccine effectiveness estimates for influenza A(H3N2) by prior vaccination status and sub-type in children 2–17 
years of ageb and adults ≥ 18 years, test–negative case–control study, United Kingdom, October 2016–March 2017 (n=659 
cases and 2,222 controls)
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UV: unvaccinated; V: vaccinated.
aAdjusted for age group, sex, month, pilot area and surveillance scheme.
bLive attenuated influenza vaccine only.
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were deposited in GISAID’s EpiFlu database under the 
following accession numbers: EPI913897, EPI913905, 
EPI913913, EPI913922, EPI913930, EPI913938, 
EPI913946, EPI913954, EPI913962, EPI913970, 
EPI913978, EPI913986, EPI913994, EPI914010, 
EPI914018, EPI914026, EPI914034, EPI914042, 
EPI914050, EPI914058, EPI914066, EPI914074, 
EPI914082, EPI914090, EPI914098, EPI914106, 
EPI914114, EPI914122, EPI914130, EPI914138, 
EPI914146, EPI914154, EPI914162, EPI914170, 
EPI914178, EPI914186, EPI914194, EPI914202, 
EPI914210, EPI914218, EPI914226, EPI914234, 
EPI914242, EPI914250, EPI914258, EPI914266, 
EPI914274, EPI914282, EPI914290, EPI914314, 
EPI914322, EPI914330, EPI914338, EPI914346, 
EPI914354, EPI914362, EPI914370, EPI914378, 
EPI914386, EPI914402, EPI914410, EPI914426, 
EPI914434, EPI914442, EPI914450, EPI914458, 
EPI914466, EPI914474, EPI914482, EPI914490, 
EPI914498, EPI914506, EPI914763, EPI914771, 
EPI914779, EPI914787, EPI914795.
Statistical methods
To analyse the swabbing results (test–negative design), 
the odds ratio (OR) of being vaccinated between cases 
and controls was used to calculate the crude VE as 
(1–OR) x 100%. We performed a multivariable logistic 
regression, as previously [1,8], to adjust VE for poten-
tial confounders with influenza laboratory results as 
the outcome and influenza vaccination status as the 
linear predictor. Estimates were calculated adjusting for 
age (by < 2, 2–11, 12–17, 18–44, 45–64 and ≥ 65 years), 
month of onset of symptoms, surveillance scheme, 
sex, and residence in area where a primary school 
programme was in place. The effect of adjustment for 
risk group was also assessed. Stratification was by 
age 2–17, 18–64 and ≥ 65 years and was split by vac-
cine type (LAIV/QIV) within those aged 2–17 years. The 
effect of prior season vaccination was also described 
by calculating all the VEs i.e. for vaccinated in both 
2016/17 and 2015/16 seasons, vaccinated only in the 
2015/16 season and vaccinated only in the 2016/17 
season and by comparing to not vaccinated in either 
Table 1
Details of influenza A(H3N2) haemagglutinin sequences obtained from GISAID used in the phylogenetic analysis, test–
negative case–control study, United Kingdom, 2016/17 influenza season
Virus isolate
Segment ID/
Accession 
number
Country
Collection 
date
Originating laboratory Submitting laboratory
A/Samara/73/2013 EPI460558 Russian Federation 12 Mar 2013
WHO National 
Influenza Centre, Saint 
Petersburg, Russian 
Federation
National Institute for 
Medical Research, London, 
UK
A/Switzerland/9715293/2013 EPI530687 Switzerland 6 Dec 2013
Hopital Cantonal 
Universitaire de 
Geneves, Switzerland
National Institute for 
Medical Research, London, 
UK
A/Hong Kong/4801/2014 EPI539576 Hong Kong (SAR) 26 Feb 2014
Government Virus Unit, 
Hong Kong (SAR)
National Institute for 
Medical Research, London, 
UK
A/New Caledonia/71/2014 EPI551570 New Caledonia 13 Aug 2014
Institut Pasteur New 
Caledonia, New 
Caledonia
WHO Collaborating Centre 
for Reference and Research 
on Influenza, Melbourne, 
Australia
A/Texas/50/2012 EPI556816 United States 15 Apr 2012
Texas Department of 
State Health Services-
Laboratory Services, 
Austin, US
Centers for Disease Control 
and Prevention, Atlanta, 
US
A/England/525/2014 EPI611375 UK 20 Nov 2014
Microbiology Services 
Colindale, Public 
Health England, 
London, UK
Microbiology Services 
Colindale, Public Health 
England, London, UK
A/England/507/2014 EPI626573 UK 24 Aug 2014
Microbiology Services 
Colindale, Public 
Health England, 
London, UK
Microbiology Services 
Colindale, Public Health 
England, London, UK
A/Bolzano/7/2016 EPI773595 Italy 15 Mar 2016 Istituto Superiore di Sanità, Rome, Italy
Crick Worldwide Influenza 
Centre, London, UK
A/Scotland/63440583/2016 EPI831436 UK 25 Aug 2016
Gart Naval General 
Hospital, Glasgow, 
Scotland, UK
Microbiology Services 
Colindale, Public Health 
England, London, UK
GISAID: Global Initiative on Sharing All Influenza Data; SAR: Special Administrative Region of the People’s Republic of China; UK: United 
Kingdom; US: United States; WHO: World Health Organization.
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Table 2a
Details for influenza A and B cases and controls, test–negative influenza case–control study, United Kingdom, October 
2016–March 2017 (n=659 cases and 2,222 controls)
Characteristic
Controls (n = 2,222)
Influenza B 
 
(n = 70)
Influenza 
A(H3N2) (n = 514)
Influenza A(H1N1)
pdm09 (n = 5)
Influenza A 
unknown (n = 70)
p value
n % n % n % n % n %
Age (years)
< 2 125 87.4 1 0.7 15 10.5 0 0 2 1.4   
 
  
 
  
 
< 0.0001 
 
  
 
  
 
 
2–11 313 83.5 5 1.3 52 13.9 1 0.3 4 1.1
12–17 146 69.9 9 4.3 50 23.9 0 0 4 1.9
18–44 774 76.1 26 2.6 187 18.4 1 0.1 29 2.9
45–64 534 74.3 17 2.4 140 19.5 2 0.3 26 3.6
≥65 313 78.6 12 3 67 16.8 1 0.3 5 1.3
Missing information 17 85 0 0 3 15 0 0 0 0
Sex
Female 1,352 78.1 45 2.6 293 16.9 3 0.2 39 2.3   
 
  
 
0.144 
 
 
Male 864 75.7 25 2.2 219 19.2 2 0.2 31 2.7
Missing 6 75 0 0 2 25 0 0 0 0
Surveillance scheme
NI 75 66.4 4 3.5 30 26.5 2 1.8 2 1.8 < 0.0001 
 
  
 
  
RCGP 720 74.2 0 0 250 25.7 1 0.1 0 0
SMN 107 74.3 2 1.4 34 23.6 0 0 1 0.7
Scotland 1,233 81.7 62 4.1 147 9.7 1 0.1 67 4.4
Wales 87 60.8 2 1.4 53 37.1 1 0.7 0 0
Risk group
No 1,379 76.2 46 2.5 335 18.5 3 0.2 46 2.5   
 
0.106 
 
   
Yes 654 79.1 18 2.2 136 16.4 2 0.2 17 2.1
Missing 189 77.1 6 2.4 43 17.6 0 0 7 2.9
Symptom onset to swab (days)
0–1 262 75.1 4 1.1 76 21.8 1 0.3 6 1.7 < 0.0001 
 
  
2–4 1,165 74.9 45 2.9 300 19.3 2 0.1 44 2.8
5–7 795 81.5 21 2.2 138 14.1 2 0.2 20 2
Vaccination status
Unvaccinated 1,642 76.4 55 2.6 389 18.1 5 0.2 57 2.7   
 
0.016 
 
  
Vaccinated (14–91 days 
ago) 347 82.4 5 1.2 61 14.5 0 0 8 1.9
Vaccinated (> 91 days ago) 233 74.7 10 3.2 64 20.5 0 0 5 1.6
Prior vaccination seasonsa (age group 2–17-year-olds LAIV only)
Unvaccinated 2016/17 and 
2015/16 240 74.5 10 3.1 65 20.2 1 0.3 6 1.9
  
 
  
 
< 0.0001 
 
  
 
   
Vaccinated 2015/16 only 61 91 2 3 4 6 0 0 0 0
Vaccinated 2016/17 only 27 75 1 2.8 8 22.2 0 0 0 0
Vaccinated 2015/16 and 
2016/17 63 95.5 0 0 3 4.6 0 0 0 0
LAIV: live attenuated influenza vaccine; NA: not applicable; NI: Northern Ireland; PHE: Public Health England; RCGP: Royal College of General 
Practitioners’ Research and Surveillance Centre (RSC) scheme; SMN: PHE Specialist Microbiology Network.
Numbers and row percentages to indicate positivity ratesa are shown.
a Only includes those whose prior vaccination status was known.
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season. VE was calculated as 1-OR, where OR is the 
odds of vaccination in cases compared with controls.
End-of-season results were compared to mid-season 
estimates to determine the accuracy of the latter 
estimates.
The collection and analysis of swab forms according 
to positivity was undertaken as part of routine influ-
enza surveillance, with the swabs taken to assist clini-
cal management. The collection of the clinical data 
accords with routine usual practice in public health. 
Specific ethical approval was not necessary.
Results 
During the study, 4,251 persons were sampled in the 
participating sentinel primary care practices and were 
tested. The reasons for study exclusion are summa-
rised in Figure 1.
The details of the 2,881 individuals remaining in the 
study were stratified according to the swab result 
(Table 2) and by vaccine status (Table 3). There were 
2,222 controls and 659 cases, of whom 589 were influ-
enza A (H3N2 n=514; A unknown n=70; H1N1pdm09 
n=5) and 70 were influenza B. The first positive influ-
enza virus detection was made on 14 October 2016.
Virus characterisation
Figure 2  shows the phylogenetic analysis of the 
HA sequences for A(H3N2) in the 2016/17 season. 
Genetic characterisation of 416 A(H3N2) influenza 
viruses from all sources since week 40 showed that 
they all belonged to genetic subclade 3C.2a, with 
Characteristic
Controls (n = 2,222)
Influenza B 
 
(n = 70)
Influenza 
A(H3N2) (n = 514)
Influenza A(H1N1)
pdm09 (n = 5)
Influenza A 
unknown (n = 70)
p value
n % n % n % n % n %
Prior vaccination seasonsa (age group 18 years and older only)
Unvaccinated 2016/17 and 
2015/16 837 75.5 26 2.3 208 18.8 1 0.1 37 3.3
  
 
  
 
< 0.0001 
 
  
 
  
Vaccinated 2015/16 only 142 90.4 2 1.3 11 7 0 0 2 1.3
Vaccinated 2016/17 only 50 76.9 4 6.2 8 12.3 0 0 3 4.6
Vaccinated 2015/16 and 
2016/17 351 79.2 5 1.1 79 17.8 0 0 8 1.8
Pilot area (RCGP and SMN only)
No 804 73.8 2 0.2 281 25.8 1 0.1 1 0.1 0.092 
 
 Yes 23 88.5 0 0 3 11.5 0 0 0 0
Month of onset of illness
October 419 99.3 0 0 3 0.7 0 0 0 0   
 
  
 
< 0.0001 
 
  
 
  
November 486 94.9 2 0.4 20 3.9 1 0.2 3 0.6
December 493 72.9 5 0.7 170 25.1 1 0.1 7 1
January 429 58.8 24 3.3 234 32.1 3 0.4 39 5.3
February 271 68.8 27 6.9 78 19.8 0 0 18 4.6
March 124 83.8 12 8.1 9 6.1 0 0 3 2
Vaccine type (2–17-year-olds only)
Not Vaccinated 344 75.8 13 2.9 89 19.6 1 0.2 7 1.5   
 
  
 
NA 
 
  
 
 
Injection 9 81.8 0 0 2 18.2 0 0 0 0
Intranasal/LAIV 101 89.4 1 0.9 11 9.7 0 0 0 0
Missing information 5 83.3 0 0 0 0 0 0 1 16.7
LAIV: live attenuated influenza vaccine; NA: not applicable; NI: Northern Ireland; PHE: Public Health England; RCGP: Royal College of General 
Practitioners’ Research and Surveillance Centre (RSC) scheme; SMN: PHE Specialist Microbiology Network.
Numbers and row percentages to indicate positivity ratesa are shown.
a Only includes those whose prior vaccination status was known.
Table 2b
Details for influenza A and B cases and controls, test–negative influenza case–control study, United Kingdom, October 
2016–March 2017 (n=659 cases and 2,222 controls)
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220 (52.9%) belonging to a cluster within this genetic 
subclade designated as 3C.2a1. The northern hemi-
sphere 2016/17 influenza A(H3N2) vaccine strain A/
HongKong/4801/2014 belongs to genetic subclade 
3C.2a and its relatedness to the circulating strains 
in the 2016/17 season is shown in  Figure 2. The com-
mon signature amino-acid substitutions characteris-
ing genetic groups in 3C.2a viruses are shown at the 
root of each cluster on the tree. The 2016/17 season’s 
A(H3N2) viruses were difficult to cultivate, and only 23 
influenza A(H3N2) viruses were antigenically charac-
terised since week 40 2016, representing a minority of 
the detections and thus a potential bias in the avail-
able antigenic data. The viruses antigenically analysed 
were similar to the A/HongKong/4801/2014 northern 
hemisphere 2016/17 A(H3N2) vaccine strain. Of the 23 
antigenically characterised viruses, eight isolates were 
also genetically characterised, with all belonging to 
genetic group 3C.2a, and six of them belonging to the 
recently emerged 3C.2a1 cluster. 
Genetic characterisation of 62 influenza B viruses from 
all sources was completed, with 58 (93.5%) viruses 
classified as belonging to the B/Yamagata/16/88, and 
genetically similar to B/Phuket/3073/2013, the influ-
enza B/Yamagata/16/88 component of the 2016/17 
northern hemisphere quadrivalent vaccine, and four 
(6.5%) classified as falling in the B/Victoria/2/87-
lineage and genetically similar to B/Brisbane/60/2008, 
the influenza B/Victoria/2/87 lineage component of 
2016/17 northern hemisphere trivalent and quadriva-
lent vaccines.
Eighteen influenza B viruses were isolated and anti-
genically characterised since week 40 2016; 13 
viruses were characterised as belonging to the B/
Yamagata/16/88-lineage and antigenically similar to B/
Phuket/3073/2013, the influenza B/Yamagata-lineage 
component of 2016/17 northern hemisphere quadriva-
lent vaccine, and five (27.8%) viruses were character-
ised as belonging to the B/Victoria/2/87-lineage and 
antigenically similar to B/Brisbane/60/2008, the influ-
enza B/Victoria-lineage component of 2016/17 north-
ern hemisphere trivalent and quadrivalent vaccines.
Model fitting for vaccine effectiveness 
estimation
When estimating VE, age group, sex, time period 
(defined by month of sample collection), surveillance 
scheme and primary school age pilot programme area 
were adjusted for in a multivariable logistic regres-
sion model. All variables that were adjusted for, except 
for sex and primary school age pilot programme in 
England, were significantly associated with a positive 
swab (Table 2). Only month was a confounder for the 
vaccine effects (changing the overall estimate by more 
than 5%). For any influenza (A and B), the crude VE was 
14.4% (95% CI: -5.0% to 30.2%), which increased to 
38.2% (23.4% to 50.2%), when month was included 
in the model. The crude and adjusted VE (aVE) esti-
mates against all influenza, influenza A(H3N2) and B 
Table 3
Key demographic variables by influenza vaccination 
status, test–negative influenza case–control study, United 
Kingdom, October 2016–March 2017 (n=659 cases and 
2,222 controls)
Characteristic
Not vaccinated 
 
(n = 2,148)
Vaccinated 
 
(n = 733) p value
n % n %
Age group (years)
< 2 143 100 0 0   
 
  
 
< 0.0001 
 
  
 
  
 
 
2–11 262 69.9 113 30.1
12–17 192 99.5 1 0.5
18–44 884 86.9 133 13.1
45–64 521 72.5 198 27.5
≥65 131 32.9 267 67.1
Missing 15 75 5 25
Sex
Female 1,274 73.6 458 26.4   
 
0.144 
 
 
Male 867 76 274 24
Missing 
information 7 87.5 1 12.5
Surveillance scheme
NI 84 74.3 29 25.7   
 
  
 
0.675 
 
  
 
 
RCGP 735 75.7 236 24.3
SMN 110 76.4 34 23.6
Scotland 1,109 73.4 401 26.6
Wales 110 76.9 33 23.1
Risk group
No 1,597 88.3 212 11.7   
 
< 0.0001 
 
 
Yes 366 44.3 461 55.7
Missing 
information 185 75.5 60 24.5
Onset to swab (days)
0–1 271 77.7 78 22.3   
 
0.305 
 
 
2–4 1,147 73.7 409 26.3
5–7 730 74.8 246 25.2
Pilot area (RCGP and SMN only)
No 824 75.7 265 24.3 0.548 
 
 Yes 21 80.8 5 19.2
Month of onset of illness
October 388 91.9 34 8.1   
 
  
 
< 0.0001 
 
   
 
  
November 393 76.8 119 23.2
December 469 69.4 207 30.6
January 510 70 219 30
February 276 70.1 118 29.9
March 112 75.7 36 24.3
NI: Northern Ireland; RCGP: Royal College of General Practitioners’ 
Research and Surveillance Centre (RSC) scheme; SMN: PHE 
Specialist Microbiology Network
Numbers and row percentages (to indicate vaccination rates) are 
shown.
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are shown in Table 4. The aVE point estimate of influ-
enza vaccine against any laboratory-confirmed infec-
tion was 39.8% (95% CI: 23.1 to 52.8) and was similar 
for influenza A(H3N2) at 31.6% (95% CI: 10.3 to 47.8), 
reflecting the fact that A(H3N2) was the dominant cir-
culating strain in the season. There were inadequate 
numbers of detections to enable estimation of effec-
tiveness against influenza A(H1N1)pdm09.
A secondary analysis was undertaken including risk fac-
tor in the model. This led to only small changes (< 5%) in 
the point estimates, but wider confidence intervals due 
to loss of data, with an overall aVE point estimate for 
all influenza of 36.8% (95% CI: 16.9 to 52.0). Further 
sensitivity analyses were undertaken. Firstly, includ-
ing all swabs no matter how long after onset they had 
been taken, which made less than 3% difference to 
the overall VE point estimate. Then a model including 
those vaccinated within 14 days as unvaccinated and 
including all swabs regardless of time since onset of 
symptoms. There was again < 3% difference to the VE 
point estimate.
Table 4
Influenza cases and controls according to vaccination status and VE estimates, test–negative influenza case–control study, 
United Kingdom, October 2016–March 2017 (n=659 cases and 2,222 controls)
Influenza type
Cases Controls Crude VE 
 
(95%CI)
Adjusteda VE 
 
(95% CI)Vaccinated Unvaccinated Vaccinated Unvaccinated
A or B 153 506 580 1,642 14.4 (-5.0 to 30.2) 39.8 (23.1 to 52.8)
A 138 451 580 1,642 13.4 (-7.2 to 30.0) 36.7 (18.3 to 51.0)
A(H3N2) 125 389 580 1,642 9.0 (-13.7 to27.2) 31.6 (10.3 to 47.8)
B 15 55 580 1,642 22.8 (-37.7 to 56.7) 54.5 (10.8 to 76.8)
CI: confidence interval; VE: vaccine effectiveness.
a Adjusted for age group, sex, month, pilot area and surveillance scheme.
Table 5
Adjusted vaccine effectiveness estimates for influenza by sub-type, age group and vaccine type, test–negative case–control 
study, United Kingdom, October 2016–March 2017 (n=659 cases and 2,222 controls)
Influenza type/subtype and 
age group
Cases Controls
Crude VE 
 
(95%CI)
Adjusteda VE 
 
(95% CI)
A and B Vaccinated Unvaccinated Vaccinated Unvaccinated                                                                                          
2–17 (IIV) 2 110 9 344 30.5 (-226.5 to 88.6) 43.2 (-183.5 to 88.6)
2–17 (LAIV4) 12 110 101 344 62.8 (29.8 to 80.3) 65.8 (30.3 to 83.2)
18–64 75 353 256 1,052 12.7 (-16.0 to 34.3) 40.6 (19.0 to 56.3)
≥ 65 63 22 204 109 -53 (-162.1 to 10.7) -6.3 (-94.5 to 42)
A Vaccinated Unvaccinated Vaccinated Unvaccinated
2–17 (IIV) 2 97 9 344 21.2 (-270.8 to 83.3) 30.9 (-260.3 to 86.7)
2–17 (LAIV4) 11 97 101 344 61.4 (25.1 to 80.1) 63.3 (22.0 to 82.7)
18–64 69 316 256 1,052 10.3 (-20.4 to 33.1) 38.5 (15.1 to 55.3)
≥ 65 55 18 204 109 -63.3 (-191.8 to 8.7) -21.2 (-134.4 to 37.3)
A(H3N2) Vaccinated Unvaccinated Vaccinated Unvaccinated
2–17 (IIV) 2 89 9 344 14.1 (-304.6 to 81.8) 24.9 (-296.1 to 85.8)
2–17 (LAIV4) 11 89 101 344 57.9 (18.2 to 78.3) 57 (7.7 to 80.0)
18–64 59 268 256 1,052 9.5 (-23.7 to 33.9) 36.6 (10.4 to 55.1)
≥ 65 53 14 204 109 -102.3 (-281.0 to -7.4) -68.4 (-248.9 to 18.7)
B Vaccinated Unvaccinated Vaccinated Unvaccinated
2–17 (LAIV4) 1 13 101 344 73.8 (-102.7 to 96.6) 78.6 (-86.0 to 97.5)
18–64 6 37 256 1,052 33.4 (-59.6 to 72.2) 52.1 (-20.0 to 80.9)
≥ 65 8 4 204 109 -6.9 (-262.9 to 68.5) 17.2 (-249.7 to 80.4)
CI: confidence interval; IIV: inactivated influenza vaccine; LAIV4: quadrivalent live attenuated influenza vaccine; VE: vaccine effectiveness.
a Adjusted for age group, sex, month, pilot area and surveillance scheme.
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Genetic characterisation information was available 
for 153 influenza A(H3N2) detections, with 66 3C.2a 
and 87 3C.2a1 detections giving an all age adjusted 
VE point estimate against 3C.2a1 of 22.7% (95% CI: 
-35.3 to 55.9) and for 3C.2a of 43.4% (95% CI: -12.3 to 
71.5). The adjusted VE point estimate against influenza 
B was 54.5% (95% CI: 10.8 to 76.8). There were 42 B/
Yamagata/16/88-lineage study samples with available 
genetic information giving an adjusted VE of 58.5% 
(95% CI: 3.1 to 82.2).
Vaccine effectiveness against influenza 
A(H3N2)
In adults
Table 5 shows the age-specific crude and aVE by sub-
type. The VE point estimate for inactivated vaccine 
(IIV) in 18–64-year-olds for influenza A(H3N2) was 
36.6% (95% CI: 10.4 to 55.1), however, there was no 
significant effectiveness against influenza A or spe-
cifically A(H3N2) in those aged 65 years and above 
(aVE: -68.4%; 95% CI: -248.9 to 18.7). Although further 
analysis found no statistically significant decline in 
effectiveness by age in ≥ 18-year-olds (p = 0.516 for lin-
ear trend on log-odds), the direction of the trend was 
towards a decrease in VE with age and this was more 
rapid in those aged ≥ 65 years.
In relation to vaccination in the prior season in the 
≥18-year-olds (Figure 3), the VE point estimate was low-
est in those vaccinated in both 2016/17 and 2015/16 
seasons (21.3%; 95% CI: -12.5 to 44.9) and higher in 
those vaccinated only in the 2016/17 season (42.9%; 
95% CI: -28.1 to 74.6), although the results were not 
statistically significant.
In children
The crude and aVE in children 2–17 years of age for 
LAIV4 and IIV is shown in  Table 5. The aVE point esti-
mate for LAIV4 against influenza A(H3N2) in children 
2–17 years old was 57% (95% CI: 7.7 to 80), and non-
significantly lower for IIV at 24.9% (95% CI: -296.1 to 
85.8).
Figure 3  shows the influence of LAIV4 vaccination in 
2–17-year-olds in the prior season, with the VE point 
estimate highest in those vaccinated in both 2016/17 
and 2015/16 seasons (77.2%, 95% CI: 19.6 to 93.5) and 
lower in those vaccinated only in the 2016/17 season 
(5.4%, 95% CI:-140.9 to 62.8). The interaction term was 
significant (p = 0.029), with the VE for vaccinated both 
years being significantly different to not vaccinated in 
either year.
Vaccine effectiveness against influenza B
In adults
The age-specific VE in adults for IIV overall and strati-
fied by age group is shown in Table 5. In adults 18–64 
years of age, the aVE point estimate was 52.1% (95% 
CI: -20 to 80.9), whereas in those 65 years of age and 
above, the aVE point estimate was not statistically sig-
nificant with very wide 95% CIs.
In children
The VE in children 2–17 years of age by vaccine type 
is shown in  Table 5. The aVE point estimate for LAIV4 
against influenza B was 78.6% (95% CI: -86 to 97.5). 
There was inadequate precision to calculate VE for IIV 
in children. There were inadequate influenza B detec-
tions to calculate VE by prior vaccine status in either 
adults or children.
Comparison of end-of-season to mid-season 
vaccine effectiveness
The mid-season analysis comprised 1,722 individuals: 
1,452 were controls and 270 cases. Of the cases, 257 
were influenza A and 13 were influenza B. Mid-season 
VE estimates, adjusting for the same variables as the 
end of season analysis, provided an aVE point estimate 
of 26.7% (95% CI: -10.4 to 51.3) for all ages against 
confirmed influenza A(H3N2) primary care consulta-
tion. All mid-season estimates were generally similar 
albeit with wider CIs compared with the end of season 
estimates.
Discussion
Our analysis found that in a season dominated by early 
circulation of influenza A(H3N2), there was moderate 
overall VE in preventing laboratory-confirmed influ-
enza in primary care. Although seasonal influenza vac-
cine was effective against influenza A(H3N2) infection 
in younger adults, there was no evidence of significant 
effectiveness of inactivated vaccine in people aged 65 
or older. On the contrary, in children there was good 
effectiveness for LAIV4 against influenza A(H3N2) and 
a suggestion of effectiveness against influenza B, for 
which there were only limited detections. Finally, we 
found no evidence that prior season vaccination sig-
nificantly reduced the effectiveness of influenza vac-
cine during the current season in adults, and rather 
increased effectiveness in children.
There are several strengths of this study. We used the 
TNCC design which is a well-established approach 
to measure influenza VE in the UK as in many other 
countries. We used our standard method to provide 
comparability to previous seasons’ UK VE estimates. 
The mid-season point estimates were similar to those 
at the end of the season, albeit with wider CIs, which 
is reassuring. There are, however, limitations to the 
study; in particular only relatively small numbers of 
children had received IIV with consequent broad CIs 
around VE point estimates and comparisons to those 
that have received LAIV4 should be made with caution, 
as the former also contained groups in whom the live 
vaccine was contraindicated such as those with severe 
asthma and immunosuppression.
The results of moderate VE in younger adults are con-
sistent with the mid-season 2016/17 estimates pub-
lished elsewhere in Europe and North America, all 
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of whom experienced influenza seasons dominated 
by circulation of A(H3N2) viruses: The Integrated 
Monitoring of Vaccines in Europe (I-MOVE) network 
reported an overall VE point estimate of 38.0% (95% 
CI: 21.3 to 51.2) in a number of European countries [14]; 
the US CDC mid-season point estimate was 43% (95% 
CI: 29 to 54) [15] and the Canadian VE network reported 
a mid-season VE of 42% (95% CI: 18 to 59) for all ages 
[16].
A small number of studies have currently reported effec-
tiveness in those aged 65 and above for the 2016/17 
season, with the I-MOVE network also reporting a 
non-significant VE in the ≥ 65-year-olds of 23.4% (95% 
CI: − 15.4 to 49.1) [14], as did study teams from Sweden 
and Finland [17]. The observation of reduced VE in this 
vulnerable population may relate to the circulating 
virus strains, the vaccine itself and/or host factors. The 
available genetic characterisation data indicate that 
the circulating strains clustered to the same genetic 
lineages as the 2016/17 A(H3N2) inactivated vaccine 
virus strain, which was an A/Hong Kong/4801/2014 
(H3N2)-like virus. Some authors have suggested that 
reduced VE may relate to the emergence of the genetic 
sub-clade 3C.2a1 [17,18]. We found a non-significantly 
lower VE for this sub-clade compared with the 3C.2a 
clade, although the antigenic characterisation data of 
circulating viruses remained limited, and there was 
no suggestion of mismatch based on the available 
information. Lower IIV VE in older adults is consistent 
with recent studies, which report that the current gen-
eration of inactivated vaccines against A(H3N2) usu-
ally result in a lower VE in those ≥ 65 years of age [19], 
where immune senescence may be an important factor. 
Indeed a recently published meta-analysis reported 
a pooled VE of 24% (95% CI: -6 to 45) in older adults 
for A(H3N2) [20]. Lower VE in adults  ≥ 65 years of age 
seems to be less of an issue for A(H1N1)pdm09 and 
influenza B, where generally little disease occurs in the 
older age groups, presumably due to underlying cross-
protective immunity in this population [20].
We found no evidence of significant negative interfer-
ence in adults from prior season’s influenza vaccine, 
although VE was lower among those also vaccinated 
the previous season. However, the antigenic distance 
between the A(H3N2) viruses in the current and prior 
season and between the current season vaccine and 
current epidemic strain was only small [7].
Our findings do highlight that better vaccines for older 
adults are required. Adjuvanted vaccines have recently 
been licenced in the UK, with both them and high dose 
vaccines available elsewhere in Europe and North 
America. It will of course be important to determine the 
effectiveness of these vaccines; early results from the 
US in elderly people for high dose vaccines have been 
encouraging [21]. In the meantime, the VE findings for 
the current generation of inactivated vaccines reinforce 
the importance of physicians considering the added 
value of influenza antiviral treatment and prophylaxis 
for those aged 65 years and older particularly in sea-
sons dominated by A(H3N2).
This present study reports significant LAIV4 effective-
ness for children 2–17 years of age against influenza 
A(H3N2) and a high, but non-significant effectiveness 
against influenza B albeit the numbers were low. These 
results continue to be reassuring, particularly in the 
light of the temporary suspension of LAIV4 in the US 
following the CDC finding of reduced VE [4]. The US 
results were at odds with those seen in several other 
countries that had used LAIV4 in 2015/16, including the 
UK [5,22]. The present study also supports results from 
an earlier VE study in the UK in 2014/15 that showed 
evidence of LAIV4 effectiveness against influenza 
A(H3N2) compared with IIV in children, when the circu-
lating strain was drifted from the vaccine virus strain 
that season. This study also found a high, but non-sig-
nificant LAIV4 effectiveness against influenza B [23]. 
The reasons for the findings of reduced LAIV VE in the 
US remain unclear, though the findings were particu-
larly notable against A(H1N1)pdm09. Other countries 
noted relatively lower effectiveness of LAIV against 
A(H1N1)pdm09 compared with IIV in 2015/16 [24,25]. It 
was been suggested that this might relate to reduced 
replicability of the A(Bolivia) H1N1pdm09 vaccine strain 
in the vaccine that year [22], though there were inad-
equate numbers of A(H1N1)pdm09 cases this season 
to be able to explore this question further. Prior sea-
son vaccination has been raised as one other poten-
tial hypothesis, as the US paediatric influenza vaccine 
programme has been running for almost a decade com-
pared with the more recently introduced UK programme 
and unlike in the UK, healthy children from 6 months 
to 2 years of age are offered inactivated vaccine as 
their priming dose. However, we found no evidence 
that vaccination in the prior season with LAIV4 reduced 
effectiveness of vaccination in the current season; a 
finding that matches those reported from elsewhere, 
such as Finland, where children could previously have 
received either LAIV or IIV [26]. It will, however, be criti-
cal to continue to monitor the effectiveness of LAIV in 
the forthcoming season, particularly with the update 
of the A(H1N1)pdm09 vaccine virus component for the 
2017/18 season to the new A/Michigan/45/2015 (H1N1)
pdm09-like virus (A/Slovenia/2903/2015) strain and 
the importance of determining its effectiveness against 
circulating strains that season [27].
In summary, we provide encouraging results for the 
new UK childhood influenza vaccine programme using 
LAIV4, albeit in a season dominated by A(H3N2) no sig-
nificant effectiveness of IIV was demonstrated in adults 
aged 65 years and above. The level of LAIV4 effective-
ness observed in 2016/17 combined with uptake in 
children [6] should maximise the population level ben-
efits of the programme. These benefits are projected 
to provide direct protection to those vaccinated, and 
by reducing children’s rates of infection, to indirectly 
protect more vulnerable members of their families and 
communities, in particular older adults and those who 
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belong to a clinical at risk group [28,29]. The findings 
in both children and those aged 65 years and above 
will need further epidemiological and virological inves-
tigation. Particularly for the former age group, the 
results from a season dominated by circulation of influ-
enza A(H1N1)pdm09 viruses will be critically important 
to provide on-going assurance of the optimal design of 
the UK programme.
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